The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...
Data from Structure Therapeutics and WAVE Life Sciences show that threats to Eli Lilly and Novo Nordisk’s dominance in weight ...
Precise Bio Inc., a Greensboro-based clinical-stage regenerative medicine company, has announced the world’s first transplant ...
While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...
Terns Pharmaceuticals reports its targeted leukemia drug maintained and even boosted molecular response rates in ...
As of Monday, December 08, Legend Biotech Corporation’s LEGN share price has dipped by 8.82%, which has investors questioning if this is right time to buy.
Michael Breen, CEO of GT Biopharma, said current cancer treatments are 80 years old.
Spyre Therapeutics (SYRE) has strong technical momentum and is trading at a new 52 week high. ・SYRE maintains a 100% “Buy” ...
With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...
The Department of Health and Human Services recently canceled $500 million in funding for vaccine research that it had previously pledged to scientists.
Breakthrough Properties is raising a $1.5B fund to buy discounted lab assets as the market struggles with high vacancy and ...
Investors seeking stocks with explosive growth potential should consider the biotech industry. Drugmakers can experience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback